Table 2.
Clinical evaluation of activity of PN and its derivatives.
| Phase | Purpose | Clinical Trial Registry | |
|---|---|---|---|
| PN | I | pharmacokinetics and toxicity | none [18] | 
| DMAPT | I | AML, ALL, and other blood-lymph tumors | none [unpublished] (United Kingdom) | 
| ACT001 | I/II | safety, tolerability, pharmacokinetics, recurrent glioblastoma | ACTRN12616000228482 (Australia & New Zealand) ChiCTR-OIC-17013604 (China) |